title: Recombinant factor VIIa should be used in massive obstetric haemorrhage.
authors: Department of Anaesthesiology, Katholieke Universiteit Leuven and University Hospitals Gasthuisberg, Leuven, Belgium.
authors: M
authors: M
authors: Van de Velde
mesh_terms: D003029:Coagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D015942:Factor VIIa / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D003029:Coagulants; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa